Clinical Trial Update: Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis [Phase 3]

View source ↗

Summary

Phase 3 safety trial evaluating whether inhaled fluticasone furoate with GW642444 affects the hypothalamic-pituitary-adrenal axis in asthma patients; results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone Furoate (fluticasone furoate)
• GW642444 (GW642444)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2013-08-08